Successful phase 3 trial for ST10 shows promise for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD)

Shield Therapeutics (Shield), an independent specialty pharmaceutical company focusedon the development of mineral-derived hospital pharmaceuticals, has announced stronglypositive top-line data from the pivotal Phase 3 programme of ST10 for the treatment ofiron deficiency anaemia (IDA) in inflammatory bowel disease (IBD).ST10, a novel orally-dosed form of ferric iron, delivered a mean improvement inhaemoglobin levels of 2.